GlobeNewswire

Dangote Foundation, GBCHealth, join forces to build Coalition on Health

Dela

NEW YORK, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Dangote Foundation (www.Dangote.com) and GBCHealth have joined forces to forge a new model of partnership, African Business Coalition on Health (GBCHealth) in Africa.

Chairman of Dangote Foundation, Aliko Dangote, shared plans to build an African Business Coalition on Health (ABCHealth), during the Bloomberg Global Business Forum, he was co-hosting, and which took place alongside the United Nations General Assembly this week in New York.

According to him, the African-led coalition of companies and philanthropists, will seek to improve the health and wellbeing of Africans, both within the workplace and within the broader communities. He stated that the partnership will develop and deploy impactful health programs across Africa, deepening knowledge, building evidence for future investment and strengthening coordination among African philanthropists, business leaders, companies and local business networks.

The Coalition is building on the leadership, reputation and convening power of the Aliko Dangote Foundation and the experience, reputation and global reach of GBCHealth. Critical issues that will be the focus of the partnership ranges from nutrition to malaria, with priorities identified and agreed by local leadership.

Through his Foundation, Dangote has made an unprecedented grant and seed contribution to GBCHealth of US$ 1.5 million over three years as a call to action and a signal to the African business community of the importance of working together and investing in health.

"The time is ripe for the private sector to proactively demonstrate its value in partnering to lead a new era in development," said Mr. Dangote. "The coalition can provide much needed guidance to ensure activities and investments are driving results in areas where the private sector can have real impact, focusing on holistic and integrated solutions that cross borders. We look forward to working with other business leaders as partners in development to drive this impact."

Co-chair of GBCHealth's Board of Directors, Aigboje Aig-Imoukhuede said, "This coalition brings together two heavyweights in the health and development arena."

"Together we have an opportunity to demonstrate how investing in health and creating healthier populations, can help business maximize shareholder value, accelerate economic growth and make entry into new markets more feasible."

The coalition will have five primary objectives over its first three years:

  • Incubate partnerships on priority health programs to enhance and accelerate results;
  • Work directly with companies to optimize workplace and community health programs;
  • Advocate for policies and initiatives that drive system-level changes;
  • Create a hub of data and insights specific to Africa and African business;
  • Curate leadership events to convene and drive action around common health issues, across sectors.

The program will kick off in Nigeria and roll out through business regions in Africa and beyond over the next three years.

The continent currently has 400 companies with revenue of more than $1 billion per year, and these companies are growing faster, and are more profitable in general, than their global peers. Coupled with these fast-moving regional leaders, small and growing businesses create 80% of the continent's employment and are stoking the engines of growth.

Against this backdrop, according to Dangote, there's a new cadre of responsible business leaders and philanthropists who understand the value and promise of sustainable large-scale investments in African countries, and are poised to make an even bigger impact on the continent's people and economies.

Investments in better training, healthcare and supply chain accountability have demonstrated direct financial return through gains in productivity and efficiency, while sup­port for social programs has accelerated economic growth and raised incomes which in turn unlocks a wider con­sumer base and makes entry into new markets more feasible.

In her comments, CEO of the Dangote Foundation, Zouera Youssoufou, said, "GBCHealth has a strong track record of bringing diverse groups together to improve the health wellbeing of communities. We look forward to collaborating to build an African business community united as a force for healthier and more inclusive development."

"What is needed now is an approach that combines the value of local insights and trusted networks with the leverage of a global platform and expertise to support the more coordinated and impactful involvement of the African private sector across the continent and within the global development community," commented Mr. Aig-Imoukhuede.

"The coalition builds on the local-to-global business approach we have developed in Nigeria through our work with the Corporate Alliance on Malaria in Africa (CAMA). The Aliko Dangote Foundation has demonstrated expertise in implementing result-oriented health programs in Nigeria and across Africa. We look forward to our collaboration to bring insights from this work to a global audience," said Nancy Wildfeir-Field, President of GBCHealth.

Immediate plans include hiring an African based CEO for ABCHealth, and building a support base for the coalition working towards a launch in early 2018. 

The foundation is generously providing office space and support for coalition staff over the first three years of development.

"It's an ambitious and bold project," said Dangote, "but the only way to move Africa forward is to take bold moves, to think big, dream big and do big things together - breaking down silos, working across borders and working across sectors- with government and with each other."

Distributed by APO on behalf of Dangote Group.

Media Contact:
Francis Awowole-Browne
Francis.Awowole@Dangote.com
+234 806 630 4898




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Dangote Group via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum